After the establishment of human EPO gene sequence [2], recombinant human EPO (rHuEPO), a structural and bio-active analogue of human EPO, has been produced as a pharmaceutical to treat patients suffering from anaemia symptoms associated with various disorders such as cancer [3]. This evidence concerns the gene EPO and anemia (phenotype).